Coviello D A, Maron B J, Spirito P, Watkins H, Vosberg H P, Thierfelder L, Schoen F J, Seidman J G, Seidman C E
Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA.
J Am Coll Cardiol. 1997 Mar 1;29(3):635-40. doi: 10.1016/s0735-1097(96)00538-4.
We studied the clinical and genetic features of familial hypertrophic cardiomyopathy (FHC) caused by an Asp175Asn mutation in the alpha-tropomyosin gene in affected subjects from three unrelated families.
Correlation of genotype and phenotype has provided important information in FHC caused by beta-cardiac myosin and cardiac troponin T mutations. Comparable analyses of hypertrophic cardiomyopathy caused by alpha-tropomyosin mutations have been hampered by the rarity of these genetic defects.
The haplotypes of three kindreds with FHC due to an alpha-tropomyosin gene mutation, Asp175Asn, were analyzed. The cardiac histopathologic findings of this mutation are reported. Distribution of left ventricular hypertrophy in affected members was assessed by two-dimensional echocardiography, and patient survival rates were compared.
Genetic studies defined unique haplotypes in the three families, demonstrating that independent mutations caused the disease in each. The Asp175Asn mutation caused cardiac histopathologic findings of myocyte hypertrophy, disarray and replacement fibrosis. The severity and distribution of left ventricular hypertrophy varied considerably in affected members from the three families (mean maximal wall thickness +/- SD: 24 +/- 4.5 mm in anterior septum of Family DT; 15 +/- 2.7 mm in anterior septum and free wall of Family DB; 18 +/- 2.1 mm in posterior septum of Family MI), but survival was comparable and favorable.
Nucleotide residue 579 in the alpha-tropomyosin gene may have increased susceptibility to mutation. On cardiac histopathologic study, defects in this sarcomere thin filament component are indistinguishable from other genetic etiologies of hypertrophic cardiomyopathy. The Asp175Asn mutation can elicit different morphologic responses, suggesting that the hypertrophic phenotype is modulated not by genetic etiologic factors alone. In contrast, prognosis reflected genotype; near normal life expectancy is found in hypertrophic cardiomyopathy caused by the alpha-tropomyosin mutation Asp175Asn.
我们研究了来自三个无血缘关系家族的受影响个体中,由α-原肌球蛋白基因中的Asp175Asn突变引起的家族性肥厚型心肌病(FHC)的临床和遗传特征。
基因型与表型的相关性为β-心肌肌球蛋白和心肌肌钙蛋白T突变导致的FHC提供了重要信息。由α-原肌球蛋白突变引起的肥厚型心肌病的类似分析因这些遗传缺陷的罕见性而受到阻碍。
分析了三个因α-原肌球蛋白基因突变Asp175Asn导致FHC的家族的单倍型。报告了该突变的心脏组织病理学发现。通过二维超声心动图评估受影响成员左心室肥厚的分布,并比较患者生存率。
遗传学研究确定了三个家族中的独特单倍型,表明每个家族中均由独立突变导致该病。Asp175Asn突变导致心肌细胞肥大、排列紊乱和替代性纤维化的心脏组织病理学发现。三个家族中受影响成员的左心室肥厚的严重程度和分布差异很大(DT家族前间隔平均最大壁厚±标准差:24±4.5mm;DB家族前间隔和游离壁:15±2.7mm;MI家族后间隔:18±2.1mm),但生存率相当且良好。
α-原肌球蛋白基因中的核苷酸残基579可能增加了突变易感性。在心脏组织病理学研究中,这种肌节细肌丝成分的缺陷与肥厚型心肌病的其他遗传病因无法区分。Asp175Asn突变可引发不同的形态学反应,表明肥厚型表型并非仅由遗传病因因素调节。相比之下,预后反映了基因型;由α-原肌球蛋白突变Asp175Asn引起的肥厚型心肌病患者的预期寿命接近正常。